Академический Документы
Профессиональный Документы
Культура Документы
Available at www.sciencedirect.com
ScienceDirect
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
KEYWORDS Abstract
Allogeneic hematopoietic Objective/background: Here, we described the clinical characteristics and outcomes of cen-
stem cell transplantation;
tral nervous system (CNS) infections occurring after allogeneic hematopoietic stem cell trans-
Central nervous system
plantation (allo-HSCT) in a single institution over the previous 6 years.
infections;
Human herpesvirus 6 Methods: Charts of 353 consecutive allogeneic transplant recipients were retrospectively
reviewed for CNS infection.
Results: A total of 17 cases of CNS infection were identified at a median of 38 days (range, 10–
1028 days) after allo-HSCT. Causative pathogens were human herpesvirus-6 (n = 6), enterococ-
cus (n = 2), staphylococcus (n = 2), streptococcus (n = 2), varicella zoster virus (n = 1), cytome-
galovirus (n = 1), John Cunningham virus (n = 1), adenovirus (n = 1), and Toxoplasma gondii
(n = 1). The cumulative incidence of CNS infection was 4.1% at 1 year and 5.5% at 5 years.
Conclusion: Multivariate analysis revealed that high-risk disease status was a risk factor for
developing CNS infection (p = .02), and that overall survival at 3 years after allo-HSCT was
33% in patients with CNS infection and 53% in those without CNS infection (p = .04).
Ó 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
* Corresponding author at: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22
Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
E-mail address: k.ohashi@cick.jp (K. Ohashi).
http://dx.doi.org/10.1016/j.hemonc.2016.08.008
1658-3876/Ó 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
CNS infection following allogeneic HSCT 23
patients were men (53%). Most patients underwent unre- High risk
lated HSCT with a myeloablative-conditioning regimen 0.8
(Table 1). No patients with CNS infections received anti-
thymocyte globulin as a conditioning regimen. The cumula- 0.6
tive incidence of CNS infection was 4.1% at 1 year and 5.5%
at 5 years after allo-HSCT. High-risk-disease status was a
significant clinical factor for CNS infection according to uni- 0.4
variate analysis (p = .01), and this factor remained signifi-
cant according to multivariate analysis (relative 0.2
risk = 4.56; 95% confidence interval, 1.28–16.2; p = .02).
The 5-year cumulative incidence of CNS infection in patients
with high-risk-disease status was 8.8%, whereas the inci- 0
dence was 1.8% in patients with low-risk-disease status
(Fig. 1). 0 1 2 3 4 5 6
Of the 17 patients who developed CNS infection (Table 2), Years after transplantation
the types of CNS infection were meningitis (n = 5),
encephalitis (n = 3), meningoencephalitis (n = 6), brain Figure 1 Cumulative incidence of the development of CNS
abscess (n = 2), and progressive multifocal leukoen- infection following allo-HSCT. The incidences for patients with
cephalopathy (n = 1). The causative pathogens were HHV-6 high-risk-disease status versus those with low-risk-disease
(n = 6), enterococcus (n = 2), staphylococcus (n = 2), strep- status are shown. Note. Allo-HSCT = allogeneic hematopoietic
tococcus (n = 2), VZV (n = 1), CMV (n = 1), JC virus (n = 1), stem cell transplantation; CNS = central nervous system.
CNS infection following allogeneic HSCT
Table 2 Clinical characteristics and outcomes of CNS infection.
Case Age (y) Sex Primary disease Stem cell source Conditioning GVHD prophylaxis Clinical findings
Type of CNS infection Causative pathogen Onset (day after transplantation) Prior steroid use Altered mental status Convulsions
1 55 F CML UBM CA+CY+TBI CyA+sMTX Meningoencephalitis HHV-6 Day 49 Yes Yes No
2 51 F MDS RBM BU+CY FK+sMTX Meningoencephalitis HHV-6 Day 36 Yes Yes No
3 42 M ATL CB CA+CY+TBI FK+sMTX Meningoencephalitis HHV-6 Day 27 No Yes No
4 48 M AML CB CA+CY+TBI FK+sMTX Meningoencephalitis HHV-6 Day 25 No Yes No
5 64 M ALL UBM Flu+Mel+TBI FK+sMTX Meningoencephalitis HHV-6 Day 19 No Yes No
6 34 M AML UBM BU+CY FK+sMTX Meningoencephalitis HHV-6 Day 21 Yes Yes Yes
7 34 F ALL UBM CY+TBI FK+sMTX Meningitis VZV Day 509 Yes No No
8 58 M ALL UBM CA+CY+TBI FK+sMTX Encephalitis CMV Day 38 Yes Yes No
9 55 F AML UBM BU+CY FK+sMTX PML JCV Day 1028 No Yes No
10 39 M ALL RPB CY+TBI CyA+sMTX Encephalitis ADV Day 121 Yes Yes No
11 58 F AML RBM BU+CY FK+sMTX Encephalitis Toxoplasma Day 101 Yes Yes No
12 37 M ALL CB CA+CY+TBI FK+sMTX Meningitis Enterococcus Day 13 Yes No No
13 45 F AML CB CA+CY+TBI CyA+sMTX Meningitis Enterococcus Day 11 No No No
14 50 F AML UBM BU+CY FK+sMTX Brain abscess S capitis Day 843 No Yes No
15 55 F ALL UBM CA+CY+TBI CyA+sMTX Brain abscess S capitis Day 150 Yes Yes No
16 25 M AML RBM BU+CY CyA+sMTX Meningitis S pneumonia Day 307 Yes Yes No
17 31 M AML CB CA+CY+TBI CyA+MMF Meningitis S haemolyticus Day 10 No Yes No
Note. ACV = acyclovir; ADV = adenovirus; ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; ATL = adult T cell leukemia; BU = busulfan; CA = cytarabine; CB = cord blood;
CML = chronic myeloid leukemia; CMV = cytomegalovirus; CNS = central nervous system; CSF = cerebrospinal fluid; CT = computed tomography; CTRX = ceftriaxone; CY = cyclophosphamide;
CyA = cyclosporine; DHPG = ganciclovir; F = female; FK = tacrolimus; GVHD = graft-versus-host disease; HHV-6 = human herpesvirus 6; JCV = John Cunningham virus; LZD = linezolid;
M = male; MDS = myelodysplastic syndrome; MEPM = meropenem; MMF = mycophenolate mofetil; MRI = magnetic resonance imaging; NA = not applicable; ND = not done; PML = progressive
multifocal leukoencephalopathy; RBM = related bone marrow; RPB = related peripheral blood stem cell; sMTX = short-term methotrexate; ST = trimethoprim/sulfamethoxazole; TBI = total
body irradiation; UBM = unrelated bone marrow; VCM = vancomycin; VZV = varicella zoster virus; WBC = white blood cell; S capitis = Staphylococcus capitis; S haemolyticus = Staphylococcus
haemolyticus; S pneumonia = Streptococcus pneumoniae.
25
26 R. Hanajiri et al.
Overall survival
CNS infection, 10 patients (59%) were receiving steroids for
GVHD treatment. Fourteen patients (82%) developed an 0.6
altered mental status, and one patient developed convul-
sions. Seven patients (41%) showed fever (>38 °C), and high 0.4
blood pressure (systolic blood pressure > 160 mmHg or dias-
tolic blood pressure > 90 mmHg) was observed in five
patients. Engraftment had been achieved in 12 patients 0.2
(71%) at the onset of CNS infection. Lumbar puncture was
performed in 16 patients, and cell counts were elevated in
0
five of these patients (31%). Median cell counts were
3 mm 3 (range, 0–4208 mm 3), and protein levels were ele- 0 1 2 3 4 5 6
vated in nine patients (53%). Cranial computed tomography Years after transplantation
was performed in nine patients, but the results were essen-
tially normal in all of the patients. Magnetic resonance Figure 2 OS following allo-HSCT for patients with and
imaging was performed in 14 patients, and nine patients without CNS infection. Note. Allo-HSCT = allogeneic hematopoi-
(64%) displayed abnormal findings (Table 2). Abnormalities etic stem cell transplantation; CNS = central nervous system;
in the medial temporal lobe were observed in three of the OS = overall survival.
six patients with HHV-6 infection. The median onset time
of HHV-6 infection seemed to be earlier as compared with nucleus, basal ganglia, thalamus, hippocampus, cerebrum,
that of other CNS infections, although the difference was cerebellum, midbrain, and pons, with abundant Toxoplasma
not statistically significant (26 days vs. 121 days; p = .18). gondii cysts and free tachyzoites (trophozoites). Toxo-
(see Table 3) plasma cysts were also visualized in the lung, thyroid, stom-
ach, uterus, ovary, and peritoneum. For the six patients
with bacterial meningitis, a bulk dose of antibiotics was
Treatment and outcome
intravenously administered. Two patients responded com-
pletely, and one patient improved with persistent memory
A summary of treatments for CNS infection is presented in
impairment.
Table 2. The probability of an overall response was 53%;
As shown in Fig. 2, OS in patients with CNS infection was
however, minor neurological symptoms remained in four
significantly inferior to that observed in those without CNS
patients (data not shown). Foscarnet was administered to
infection (33% vs. 53% at 3 years; p = .04). Only six patients
all six patients with HHV-6 infection. Of these patients,
were alive at a median follow-up of 39 months (range, 1–58
two improved completely, but the remaining four improved
months) after diagnosis of CNS infection. The median OS
with minor neurological symptoms or did not respond to the
after the onset of CNS infection as determined using the
treatment. We were able to analyze sequential HHV-6 PCR
Kaplan-Meier method was only 107 days. Only four patients
values in three patients (Cases 1, 2, and 6), and in each
simultaneously developed systemic infection documented
patient, HHV-6 copy number in CSF decreased after initia-
by blood culture or autopsy. Causative pathogens for sys-
tion of foscarnet treatment (Case 1: HHV-6 PCR positive
temic infection were enterococcus (Cases 12 and 13), Strep-
to negative; Case 2: 3000 copies/mL to undetectable; and
tococcus pneumoniae (Case 16), and Toxoplasma gondii
Case 6: from 77,000 copies/mL to 150 copies/mL). For VZV
(Case 11). The main cause of death was CNS infection in
meningitis (Case 7), CMV encephalitis (Case 8), and progres-
six patients, other infections in three patients, and disease
sive multifocal leukoencephalopathy due to JC virus (Case
progression in two patients (Table 2).
9), acyclovir, foscarnet, and mefloquine were administered,
respectively. The patient with toxoplasmosis (Case 11)
developed respiratory failure with diffuse bilateral infil- Discussion
trates at the onset. Pneumocystis pneumonia was initially
suspected, and, therefore, sulfamethoxazole-trimethoprim In our series, 4.8% of allo-HSCT recipients developed CNS
was administered. At autopsy, the brain of the patient infection at a median of 38 days after transplantation.
showed widespread necrotizing tissue in the caudate The incidence of CNS infection varies from 0.8% to 15%
[7–14], with the discrepancy in these incidences possibly convulsions [27]. Thus, the initial manifestation of CNS
due to differences in study design, patient population of infection may be very similar to that of other disorders,
the studies, definition of CNS infection, or prophylactic such as cerebrovascular disease, metabolic disorder, and
strategies for infections. In a retrospective study of 2628 drug toxicity [5,10,23,25]. Therefore, a positive diagnostic
patients undergoing allo-HSCT, Schmidt-Hieber et al. [7] strategy, including PCR testing of CSF for virus infection
reported that the incidence of viral encephalitis was 1.2%, and magnetic resonance imaging rather than computer
a result comparable with ours. Regarding the risk factors tomography, may be needed to reach an accurate diagnosis,
for CNS infection, in a retrospective study of 655 patients although not all positive cultures or PCR-testing results are
who underwent allogeneic or autologous transplantation, reflective of the true infection and results should be inter-
Maschke et al. [11] revealed that severe GVHD or the use preted with caution.
of high doses of immunosuppressive drugs may induce a risk This study had a limitation due to its retrospective nat-
for developing toxoplasma encephalitis. In our study, a high- ure. Additionally, we may have overlooked some patients
risk-disease status was an independent risk factor for CNS with CNS infection, despite detailed database analysis and
infection, which may be attributed to the immunosuppres- extensive chart review. Nevertheless, our aim was to review
sive status due to multiple courses of intensive chemother- the clinical outcomes of 353 allogeneic transplant patients
apy before transplantation. The prognosis of patients with after CNS infection over a 6-year period and to provide use-
CNS infection after allo-HSCT is extremely poor. Schmidt- ful insights into this phenomenon.
Hieber et al. [7] reported that the median survival after
the onset of viral encephalitis was only 94 days, with higher Conflicts of interest
mortality in patients with rather than those without viral
encephalitis. In our study, the median OS after the onset
There are no competing financial interests.
of CNS infection was 107 days, and OS at 3 years after
allo-HSCT was 33%, similar to a report by Maschke et al.
[11] Although in four cases it appeared that CNS disease
was secondary to a systemic infection, most of the patients Acknowledgment
developed sole manifestation of the pathogen. Therefore,
the worse 3-year OS observed among patients with CNS We would like to thank the nursing staff of Tokyo Metropoli-
infections was a direct consequence of CNS infection. tan Cancer and Infectious Diseases Center, Komagome
Among our 17 cases of CNS infection, viruses accounted Hospital, Tokyo, Japan for their excellent patient care.
for 58%, bacteria for 36%, and protozoa for 6%; however,
no fungal CNS infection was observed in our series. Maschke
et al. [11] reported that cerebral aspergillosis was the sec-
References
ond most common CNS infection post-transplantation. In
[1] Antonini G, Ceschin V, Morino S, Fiorelli M, Gragnani F,
another autopsy series of 180 transplant recipients, 27 Mengarelli A, et al. Early neurologic complications following
patients had an infection in the brain parenchyma, and fungi allogeneic b marrow transplant for leukemia: a prospective
were isolated in up to 60% of their cases [10]. The discrep- study. Neurology 1998;50:1441–5.
ancy in the causative pathogens may be due to differences [2] Iguchi A, Kobayashi R, Yoshida M, Kaneda M, Watanabe N, Cho
in prophylactic strategies or the choice of diagnostic modal- Y, et al. Neurological complications after stem cell transplan-
ities for CNS infection. tation in childhood. Bone Marrow Transplant. 1999;24:647–52.
Regarding HHV-6 meningoencephalitis, although all six [3] Bleggi-Torres LF, de Medeiros BC, Neto JZ, Loddo G, Pasquini
patients received foscarnet relatively early in their clinical R, et al. Neuropathological findings after bone marrow trans-
plantation: an autopsy study of 180 cases. Bone Marrow
courses, only two showed good cognitive recovery, and four
Transplant 2000;25:301–7.
continued to have memory impairment or disorientation.
[4] Najima Y, Ohashi K, Miyazawa M, Nakano M, Kobayashi T,
Moreover, most patients died during follow-up, although Yamashita T, et al. Intracranial hemorrhage following allo-
no patients died of HHV-6 meningoencephalitis, similar to geneic hematopoietic stem cell transplantation. Am J Hematol
previous reports showing that >50% of patients with HHV-6 2009;84:298–301.
meningoencephalitis died of encephalitis-unrelated causes, [5] Schmidt-Hieber M, Zweigner J, Uharek L, Blau IW, Thiel E.
such as GVHD and other infections [24,25]. Although inci- Central nervous system infections in immunocompromised
dental positivity of CSF PCR for HHV-6 in chromosomally patients: update on diagnostics and therapy. Leuk Lymphoma
integrated HHV-6 (ciHHV-6) patients with CSF pleocytosis 2009;50:24–36.
may result in erroneous diagnosis of HHV-6 meningoen- [6] Singh N, Husain S. Infections of the central nervous system in
transplant recipients. Transpl Infect Dis 2000;2:101–11.
cephalitis [26], considering that all six patients developed
[7] Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kühl
typical clinical features of HHV-6 meningoencephalitis, the
JS, Mousset S, et al. Viral encephalitis after allogeneic stem
possibility of misdiagnosis due to ciHHV-6 seems unlikely. cell transplantation: a rare complication with distinct charac-
We also focused on the initial clinical findings of CNS teristics of different causative agents. Haematologica
infection; however, not surprisingly, we found no specific 2009;96:142–9.
features in our series. Although most patients presented [8] Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ,
with altered mental status as the initial manifestation, Straube A. Prospective evaluation of neurological complica-
<50% of patients developed fever (>38°C), and convulsions tions after allogeneic bone marrow transplantation. Neurology
were observed in only one patient with HHV-6 infection. 2003;60:842–8.
In a retrospective study of 1461 allo-HSCT cases, CNS infec- [9] Jantunen E, Volin L, Salonen O, Piilonen A, Parkkali T, Anttila
VJ, et al. Central nervous system aspergillosis in allogeneic
tion was documented in 14 (17.7%) out of 79 patients with
28 R. Hanajiri et al.
stem cell transplant recipients. Bone Marrow Transplant [19] Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central
2003;31:191–6. nervous system disease in stem-cell transplant recipients: an
[10] de Medeiros BC, de Medeiros CR, Werner B, Neto JZ, Loddo G, increasing complication of drug-resistant CMV infection and
Pasquini R, et al. Central nervous system infections following protracted immunodeficiency. Bone Marrow Transplant
bone marrow transplantation: an autopsy report of 27 cases. J 2010;45:979–84.
Hematother Stem Cell Res 2000;9:535–40. [20] Kishida S, Tanaka K. Mefloquine treatment in a patient
[11] Maschke M, Dietrich U, Prumbaum M, Kastrup O, Turowski B, suffering from progressive multifocal leukoencephalopathy
Schaefer UW, et al. Opportunistic CNS infection after bone after umbilical cord blood transplant. Intern Med
marrow transplantation. Bone Marrow Transplant 2010;49:2509–13.
1999;23:1167–76. [21] Mulanovich VE, Ahmed SI, Ozturk T, Khokhar FA, Kontoyiannis
[12] Barba P, Pinana JL, Valcarcel D, Querol L, Martino R, Sureda A, DP, de Lima M. Toxoplasmosis in allo-SCT patients: risk factors
et al. Early and late neurological complications after reduced- and outcomes at a transplantation center with a low incidence.
intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2011;46:273–7.
Biol Blood Marrow Transplant 2009;15:1439–46. [22] Narimatsu H, Miyamura K, Iida H, Hamaguchi M, Uchida T,
[13] Weber C, Schaper J, Tibussek D, Adams O, Mackenzie CR, Morishita Y, et al. Early central nervous complications after
Dilloo D, et al. Diagnostic and therapeutic implications of umbilical cord blood transplantation for adults. Biol Blood
neurological complications following paediatric haematopoi- Marrow Transplant 2009;15:92–100.
etic stem cell transplantation. Bone Marrow Transplant [23] Kishi Y, Miyakoshi S, Kami M, Ikeda M, Katayama Y, Murashige
2008;41:253–9. N, et al. Early central nervous system complications after
[14] Teive H, Carsten AL, Iwamoto FM, Almeida SM, Munhoz RP, reduced-intensity stem cell transplantation. Biol Blood Marrow
Werneck LC, et al. Fungal encephalitis following bone marrow Transplant 2004;10:561–8.
transplantation: clinical findings and prognosis. J Postgrad Med [24] Sakai R, Kanamori H, Motohashi K, Yamamoto W, Matsuura S,
2008;54:203–5. Fujita A, et al. Long-term outcome of human herpesvirus-6
[15] Campos A, Vaz CP, Campilho F, Morais A, Guimarães MA, Lopes encephalitis after allogeneic stem cell transplantation. Biol
C, et al. Central nervous system (CNS) tuberculosis following Blood Marrow Transplant 2011;17:1389–94.
allogeneic stem cell transplantation. Bone Marrow Transplant [25] Fujimaki K, Mori T, Kida A, Tanaka M, Kawai N, Matsushima T,
2000;25:567–9. et al. Human herpesvirus 6 meningoencephalitis in allogeneic
[16] Suzuki J, Ashizawa M, Okuda S, Wada H, Sakamoto K, Terasako hematopoietic stem cell transplant recipients. Int J Hematol
K, et al. Varicella zoster virus meningoencephalitis after 2006;84:432–7.
allogeneic hematopoietic stem cell transplantation. Transpl [26] Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT,
Infect Dis 2012;14:E7–E12. Descamps V, et al. Chromosomally integrated human her-
[17] Frange P, Peffault de Latour R, Boddaert N, Oualha M, pesvirus 6: questions and answers. Rev Med Virol
Avettand-Fenoel V, et al. Adenoviral infection presenting as 2012;22:144–55, 7.
an isolated central nervous system disease without detectable [27] Zhang XH, Xu LP, Liu DH, Chen H, Han W, Chen YH, et al.
viremia in two children after stem cell transplantation. J Clin Epileptic seizures in patients following allogeneic hematopoi-
Microbiol 2011;49:2361–4. etic stem cell transplantation: a retrospective analysis of
[18] Romee R, Brunstein CG, Weisdorf DJ, Majhail NS. Herpes incidence, risk factors, and survival rates. Clin Transplant
simplex virus encephalitis after allogeneic transplantation: an 2012;27:80–9.
instructive case. Bone Marrow Transplant 2010;45:776–8.